Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

53%

8 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

5 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
7(53.8%)
Phase 2
3(23.1%)
Phase 1
2(15.4%)
Phase 4
1(7.7%)
13Total
Phase 3(7)
Phase 2(3)
Phase 1(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT05066217Phase 3Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

Role: collaborator

NCT07500090Phase 3Recruiting

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

Role: lead

NCT06366464Phase 3Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Role: lead

NCT07219485Phase 3Enrolling By Invitation

A Study of Pitolisant in Participants With Prader-Willi Syndrome

Role: lead

NCT05149898Phase 2Completed

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

Role: lead

NCT04257929Phase 2Active Not Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Role: lead

NCT06930872Phase 1Completed

Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates

Role: lead

NCT07051252Phase 1Completed

A Study of HBS-201 (Pitolisant Delayed-release)

Role: lead

NCT05458128Phase 3Completed

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

Role: lead

NCT04462770Phase 3Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Role: collaborator

NCT05536011Recruiting

WAKIX® (Pitolisant) Pregnancy Registry

Role: lead

NCT04886518Phase 2Completed

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Role: lead

NCT05156047Phase 3Completed

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Role: lead

NCT05581576Phase 4Unknown

Pitolisant in Refractory Restless Legs Syndrome

Role: collaborator

NCT03433131Unknown

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Role: lead

All 15 trials loaded